JPRN-jRCT2080220835未知3 期
An open-label study of TAK-536 in hypertensive patients with renal disorder
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Hypertension with renal disorder
- •2.Inpatient/Outpatient status: Outpatient, etc.
排除标准
- •1.Presence of secondary hypertension other than renal parenchymal hypertension, grade III hypertension, or malignant hypertension
- •2.Renal disorder associated with collagen disease (e.g., SLE) or rapidly progressive glomerulonephritis
- •3.Cardiac disease, cerebrovascular disorder, vascular disease, or advanced hypertensive retinopathy
- •4.Renovascular hypertension or renal artery stenosis
- •5.Undergoing dialysis
- •6.Hyperkalemia, etc.
研究者
相似试验
未知
3 期
An open-label study of TAK-536 in patients with grade III hypertensioHypertensionJPRN-jRCT2080220836Takeda Pharmaceutical Company Limited
已完成
3 期
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years with HypertensioPediatric hypertensionJPRN-jRCT2080223205Takeda Pharmaceutical Company Limited27
未知
3 期
Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertensioHypertensionJPRN-jRCT2080221566TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Phase III long-term study of TAK-536CCB in patients with grade I or II essential hypertensioHypertensionJPRN-jRCT2080221586TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
1 期
A Phase 1 study of TAK-385 in Patients With Androgen Deprivation Treatment-Naive Prostate CancerJPRN-jRCT2080222485TAKEDA PHARMACEUTICAL COMPANY LTD.43